Acromegaly and Gigantism Drugs Market Size, Share Global Analysis Report, 2020–2026

Industry Insights

The acromegaly and gigantism drugs market report analyzes and notifies the industry statistics at the global as well as regional and country levels in order to acquire a thorough perspective of the entire acromegaly and gigantism drugs market. The historical and past insights are provided for FY 2016 to FY 2019 whereas projected trends are delivered for FY 2020 to FY 2026. The quantitative and numerical data is represented in value (USD Million) from FY 2016 – 2026.

This specialized and expertise-oriented industry research report scrutinizes the technical and commercial business outlook of the acromegaly and gigantism drugs industry. The report analyzes and declares the historical and current trends analysis of the acromegaly and gigantism drugs industry and subsequently recommends the projected trends anticipated to be observed in the acromegaly and gigantism drugs market during the upcoming years.

Key Insights from Primary Research

• According to the primary CXOs of the global acromegaly and gigantism drugs market, the market is estimated to witness a substantial growth of nearly 3.5% over the forecast period.
• The market was valued at USD 709.5 million, in 2019 and is expected to be valued at over USD 902.6 million.
• On the basis of the product segment, somatostatin analogs dominated the global acromegaly and gigantism drugs market in 2019. In terms of revenue, it accounted for more than a 35% share of the total market in 2019.
• Based on various treatments, the global acromegaly and gigantism drugs market was led by medication with more than half of the share of the total market, in 2019.
• End-use-wise, hospitals were the largest category of the global acromegaly and gigantism drugs market in 2019. It accounted for more than a 48% share of the market in 2019.
• By geography, the North American region headed the market with a share of above 30%, in 2019.

Key Recommendations from Analysts

• Our analysts recommend that the Asia Pacific region is predicted to witness significant growth over the forecast period.    
• According to industry expertise, the growth hormone (GH) secreting adenoma in the pituitary gland is the major cause of acromegaly and gigantism.
• Roll-out compensation plans and programs for rare disease patients are expected to fuel the market’s growth over the years to come.
• Surging medical and pharmaceutical industries in developing countries such as China, India, South Korea, Brazil, and many other Southeast Asia Countries are likely to cater to the lucrative market’s margin in the future years.
• According to our analysts, the increasing use of somatostatin analogs with improved administration or dosage schemes; the recent focus on improving patient comfort in this field of chronic disease are expected to drive the growth of the market globally in the near future.

Market Share Analysis by Region

The quantitative data is further underlined and reinforced by comprehensive qualitative data which comprises various across-the-board market dynamics. The rationales which directly or indirectly impact the acromegaly and gigantism drugs industry are exemplified through parameters such as growth drivers, restraints, challenges, and opportunities among other impacting factors.

Throughout our research report, we have encompassed all the proven models and tools of industry analysis and extensively illustrated all the key business strategies and business models adopted in the acromegaly and gigantism drugs industry. The report provides an all-inclusive and detailed competitive landscape prevalent in the acromegaly and gigantism drugs market.

The report utilizes established industry analysis tools and models such as Porter’s Five Forces framework to analyze and recognize critical business strategies adopted by various stakeholders involved in the entire value chain of the acromegaly and gigantism drugs industry. The acromegaly and gigantism drugs market report additionally employs SWOT analysis and PESTLE analysis models for further in-depth analysis.

The report study further includes an in-depth analysis of industry players' market shares and provides an overview of leading players' market position in the acromegaly and gigantism drugs sector. Key strategic developments in the acromegaly and gigantism drugs market competitive landscape such as acquisitions & mergers, inaugurations of different products and services, partnerships & joint ventures, MoU agreements, VC & funding activities, R&D activities, and geographic expansion among other noteworthy activities by key players of the acromegaly and gigantism drugs market are appropriately highlighted in the report.

The acromegaly and gigantism drugs market research report delivers an acute valuation and taxonomy of the acromegaly and gigantism drugs industry by practically splitting the market on the basis of different types, categories, and regions.

Through the analysis of the historical and projected trends, all the segments and sub-segments were evaluated through the bottom-up approach, and different market sizes have been projected for FY 2020 to FY 2026. The regional segmentation of the acromegaly and gigantism drugs industry includes the complete classification of all the major continents including North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa. Further, country-wise data for the acromegaly and gigantism drugs industries is provided for the leading economies of the world.

Acromegaly and gigantism is a rare conditions and the total incidence of acromegaly ranges from 3.8 to 14.7 cases per 1 lakh person per year, as per Pituitary Journal. The increased prevalence of the disease is one of the key factors expected to drive global market growth in acromegaly and gigantism over the forecast period.

The acromegaly and gigantism drugs market is segmented based on type, treatment, and end-use. On the basis of type segmentation, the market is classified into GH receptor antagonists, somatostatin analogs, dopamine agonists, and others. In terms of treatment segmentation, the market is bifurcated into medication, radiation therapy, and surgery. End-use-wise, the market is segregated into clinics, hospitals, and others.

Report Scope

Some of the essential players operating in the acromegaly and gigantism drugs market, but not restricted to include:

• Pfizer Inc.
•  Ionis Pharmaceuticals Inc.
•  Chiasma Inc.
•  Novartis AG
•  Crinetics Pharmaceuticals
•  Ipsen
•  Midatech Pharma Plc
•  Novartis AG

The taxonomy of the acromegaly and gigantism drugs industry by its scope and segmentation is as follows:

By Drug Type Segmentation Analysis

• GH Receptor Antagonists
• Somatostatin Analogs
• Dopamine Agonists
• Others

By Treatment Segmentation Analysis

• Medication
• Radiation Therapy
• Surgery

By End-Use Segmentation Analysis

• Clinics
• Hospitals
• Others

Regional Segmentation Analysis

• North America
  • The U.S.
  • Canada
• Europe
  • Germany
  • The UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa